How does this company make money?
The company earns money each time a vial of Onpattro or a dose of Oxlumo is sold, with both drugs distributed through specialty pharmacies. It also collects milestone payments — lump sums triggered when a partner's drug reaches certain development stages — and ongoing royalties when pharmaceutical partners license Alnylam's RNAi technology to develop their own co-developed programs.
What makes this company hard to replace?
Physicians who manage these patients are trained on very specific dosing protocols — subcutaneous injection for Oxlumo works differently from intravenous infusion for Onpattro, and switching between delivery methods is not a simple substitution. FDA-approved Risk Evaluation and Mitigation Strategy programs restrict prescribing to certified treatment centers, meaning only those centers can legally dispense the drugs. On top of that, insurance prior authorization pathways are set up for specific branded RNAi products, so switching to a different therapy would require restarting that approval process from scratch.
What limits this company?
The delivery chemistry only works reliably in the liver. GalNAc conjugation depends on surface receptors found specifically on liver cells, and lipid nanoparticles tend to collect in liver tissue too. Any disease caused by a protein made somewhere else in the body — even one that could theoretically be silenced by siRNA — is out of reach until a new delivery method is discovered. That keeps the entire pipeline confined to hereditary conditions rooted in the liver.
What does this company depend on?
Alnylam cannot operate without GalNAc conjugation chemistry to route drugs into liver cells, lipid nanoparticle formulation technology to enable intravenous delivery, specialized oligonucleotide synthesis facilities to manufacture the siRNA molecules themselves, cold-chain distribution networks that keep RNA-based drugs stable during shipping, and FDA orphan drug designation pathways that shape how these medicines reach patients.
Who depends on this company?
Patients with hereditary transthyretin amyloidosis depend on Onpattro infusions — without them, there is no equivalent approved therapy using the same mechanism. Hepatologists treating primary hyperoxaluria rely on Oxlumo subcutaneous injections for their patients. Specialty pharmacies that handle temperature-controlled RNAi therapeutics through restricted distribution programs would lose a core part of their business if Alnylam stopped supplying these drugs.
How does this company scale?
Identifying a new disease target and designing an siRNA sequence to silence it is relatively cheap — computational biology tools can do most of that work quickly. Everything after that resists easy replication: each new target needs its own custom synthesis chemistry, its own delivery conjugate, and its own full clinical trial in a separate rare disease population. The ideas scale cheaply; turning each idea into an approved drug does not.
What external forces can significantly affect this company?
Medicare Part B reimbursement policies directly affect whether hospitals get paid for administering Onpattro infusions, which shapes how widely the drug is used in the United States. European Medicines Agency guidelines on oligonucleotide therapeutics influence how long it takes to bring new RNA drugs to patients in Europe. Trade restrictions on specialized lipid components sourced from international chemical suppliers could interrupt the supply of materials needed to manufacture lipid nanoparticle formulations.
Where is this company structurally vulnerable?
The Tuschl and Fire mechanism patents expire between 2024 and 2026. Once they do, any company can use the core siRNA-mRNA silencing step without a license. At that point, the only remaining barrier is the Enhanced Stabilization Chemistry — but that patent covers Alnylam's specific formulation approach, not the general idea of delivering siRNA to the liver. A well-funded competitor could engineer a different delivery method that achieves the same result without copying Alnylam's exact chemistry.
CompanyGraph